IP Verse

Methods Of Treating Chronic Kidney Disease With Dapagliflozin

Patent No. EP4188389 (titled "Methods Of Treating Chronic Kidney Disease With Dapagliflozin") was filed by Astrazeneca on Apr 1, 2021. The application was issued on Sep 17, 2025.

Patent Summary

Treatment of chronic kidney disease (CKD) in patients with and without type 2 diabetes using sodium glucose co-transporter type 2 (SGLT2) inhibitors, such as dapagliflozin, to reduce CKD progression, cardiovascular events, and mortality. The treatment also prevents or delays the onset of type 2 diabetes in prediabetic patients.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZMay 12, 2026TER MEER STEINMEISTER & PARTNER
GENERICS UKSep 17, 2025ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4188389

ASTRAZENECA
Application Number
EP21716724A
Filing Date
Apr 1, 2021
Status
Granted And Under Opposition
Aug 15, 2025
Publication Date
Sep 17, 2025
External Links
Slate, Register , Google Patents